Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this review, researchers found no evidence of interactions between 5α-reductase inhibitors or spironolactone and endocrine therapies for breast cancer, with no consistent changes in estrogen levels or increased breast cancer risk associated with spironolactone usage.

This review discusses the management of androgenic disorders in women, highlighting that treatment is generally more effective than recognized, though improvement may take weeks or months to appear.

This review discusses nearly 70 patent applications for the treatment of androgenetic alopecia and other hair conditions, highlighting the mechanisms of action explored but reports no clinical results.

This narrative review discusses various causes and treatments of hirsutism in women, emphasizing the importance of identifying androgen-secreting tumors, but does not present new study results.

This article reviews the causes and treatments of hypertrichosis and hirsutism and reports no new clinical findings; the authors compare diagnostic strategies and discuss available treatment options.

This article discusses primary cicatricial alopecia, highlighting the need for early and precise diagnosis to effectively manage and treat these complex inflammatory hair disorders, but presents no new clinical results.

This review reports that anti-androgens, often combined with contraception, are supported for managing PCOS symptoms related to high androgen levels, but uncertainties remain about long-term safety and metabolic effects, indicating a need for future research on various treatment approaches.

This review addresses the use of anti-androgens in managing symptoms of polycystic ovary syndrome, noting both their clinical effectiveness and associated safety concerns, while highlighting the need for more research into their long-term safety and metabolic effects.

This review discusses the current therapies for androgenic alopecia, emphasizing topical formulations like minoxidil and finasteride and exploring the potential of dutasteride-loaded nanocarriers for targeting hair follicles to minimize systemic side effects from oral treatment.

This study explores novel alopecia treatments targeting lactate dehydrogenase pathways and improving drug delivery through technologies like phototherapy and soluble microneedles, though practical application challenges remain, necessitating further research for clinical use.

In this study, researchers found that a cold atmospheric plasma-activated hydrogel containing interleukin-2 significantly enhanced hair regeneration in a depilated mouse model, promoting larger hair follicles and faster hair growth phase transition, suggesting it as a potential treatment for hair loss.

This article highlights that in Australia, transgender and gender-diverse patients experience specific dermatological challenges during gender-affirming treatments, such as acne and patterned hair loss. It emphasizes the need for tailored dermatological care and guidance for these patients.

This report describes a rare case of lipedematous alopecia in a young Caucasian man, a condition primarily seen in African-American females, presenting with specific scalp and histological characteristics.

This study found that finasteride treatment in males with androgenetic alopecia was linked to significant changes in sperm parameters and increased testosterone levels, but no sexual dysfunction was observed, and sperm parameters returned to baseline after treatment stopped.

In this study, oral finasteride improved the quality of life for male patients with androgenetic alopecia, but it did not significantly reduce anxiety or correlate with reported anxiety levels.

Pill splitting increased generic finasteride sales but didn't affect branded finasteride sales.

This study found that short durations of heat and specific chemical penetration enhancers significantly improved the delivery of finasteride to human scalp skin and hair follicles.

Finasteride increases hair density in female androgenetic alopecia, but individual results may vary.

Finasteride improves hidradenitis suppurativa but not for child-bearing women.

This webpage provides access options for JAMA Dermatology but does not contain research findings or results.

In this study, researchers developed a new self-administered finasteride delivery system using powder-carrying microneedles that improved hair growth efficacy and addressed safety concerns compared to topical finasteride gel by allowing sustained intradermal release of the drug for three days with a single application.

This case report discusses a 32-year-old man's treatment for advanced androgenetic alopecia using a combination of topical minoxidil and oral finasteride, but no clinical outcomes are detailed.

Combining platelet-rich plasma with 5% minoxidil solution improves hair regrowth in androgenetic alopecia patients.

This study found that incorporating 0.5% TPGS into topical minoxidil solutions enhanced hair growth in mice, although increasing TPGS to 2% decreased effectiveness.

In this animal study, researchers found that finasteride reduced bacterial infection and inflammation in chronic bacterial prostatitis, with the greatest effect when combined with ciprofloxacin.

This study reported that weekly intramuscular dexpanthenol may improve quality of life and satisfaction with hair appearance in women with female pattern hair loss, with no side effects observed.

This review discusses the efficacy and safety of oral finasteride for treating male pattern baldness and the potential persistent side effects, but no new results are reported.

Intramuscular triamcinolone and pulse therapy with oral predonine are effective for alopecia areata with manageable side effects, but better relapse prevention is needed.

This study suggests that epidermal turnover could be a regulated mechanism of iron excretion, with systemic iron levels influencing keratinocyte behavior and differentiation markers in the skin.

This study found that a low dose of finasteride over 12 weeks did not alter the lipid profile or adiposity index in atheroprone Ldlr−/− mice.